Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?

Key Takeaways CorMedix posted preliminary Q3 2025 net revenues topping $125M, with over $85M from DefenCath alone.The company raised its full-year 2025 revenue outlook to at least $375M and expects $70M in EBITDA.Melinta's integration and DefenCath's exclusivity through 2033 reinforce CRMD's growth and profitability.CorMedix (CRMD) is expected to report its third-quarter 2025 earnings results soon. The Zacks Consensus Estimate for sales and earnings is pegged at $70 million and 48 cents per share, respectiv ...